相关实验视频

Updated: Feb 21, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

特拉贝克丁素加上针对CD13的组织因子tTF-NGR,用于治疗复发性或耐火性软组织肉瘤:转化数据,临床安全性和疗效

Kathrin Hessling¹, Caroline Brand¹, Christian Schwöppe¹

¹Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, Albert‑Schweitzer‑Campus 1, 48149, Muenster, Germany.

Scientific reports

|February 19, 2026

概括

在TRABTRAP试验中,用于软组织肉瘤,结合了trabectedin和tTF-NGR. 推的起始剂量表现出良好的耐受性,支持进一步的随机研究.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
翻译医学是一种翻译医学.

背景情况:

特拉贝克丁是复发性/耐火性软组织肉瘤的标准治疗方法.
瘤向融合NGR (tTF-NGR) 向瘤血管,导致闭塞和心脏病发作.
连续使用可能会通过将它困在瘤中来增强特拉贝克丁的疗效.

研究的目的:

评估将特拉贝克丁与tTF-NGR结合的安全性和耐受性.
为了确定TRABTRAP试验的最大耐受剂量 (MTD) 和建议的起始剂量.
总结TRABTRAP试验最初患者队列的翻译数据和安全性调查结果.

主要方法:

在TRABTRAP试验的第一阶段安全运行队列中.
特拉贝克丁和tTF-NGR的组合疗法连续使用.
对tTF-NGR的剂量升级,以确定剂量限制性毒性 (DLT).

主要成果:

一种1.5mg/m2的trabectedin和0.5mg/m2的tTF-NGR的组合剂量被确定为推的起始剂量.
在接受推起始剂量的患者中,没有观察到剂量限制性毒性 (DLT).
较高剂量或tTF-NGR的延长应用导致3级DLT,包括心肌梗塞和血栓塞栓事件.

结论:

在推剂量下,trabectedin和tTF-NGR的组合是可行的和可以容忍的.
确定的MTD和推的起始剂量支持正在进行的TRABTRAP试验的随机部分.
翻译和临床数据支持继续研究这种用于软组织肉瘤的联合治疗方法.

关键词:

针对CD13的组织因子tTF-NGRR 软组织肉瘤 (软组织肉瘤)在里面被抓走了.

更多相关视频

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...